Palatin Technologies, Inc.
LSE: 0KF3.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Carl Spana
- Employees
- 30
- Headquarters
- Cranbury, United States
- IPO year
- 2018
- Market cap
- $18.0M
- Website
- https://palatin.com
Loading 0KF3…
Loading profile data…Frequently asked questions about 0KF3
What does Palatin Technologies, Inc. (0KF3.L) do?
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing o...
Where does 0KF3.L trade?
Palatin Technologies, Inc. (0KF3.L) trades on the London Stock Exchange.
What sector is 0KF3.L in?
Palatin Technologies, Inc. (0KF3.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Palatin Technologies, Inc.?
Carl Spana is the chief executive officer of Palatin Technologies, Inc. (0KF3.L).
Where is Palatin Technologies, Inc. headquartered?
Palatin Technologies, Inc. is headquartered in United States.
Does 0KF3.L pay a dividend?
Palatin Technologies, Inc. (0KF3.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0KF3.L go public?
Palatin Technologies, Inc. (0KF3.L) completed its initial public offering in 2018.